BRIEF-Abeona Therapeutics receives FDA orphan drug designation for ABO-201 juvenile Batten disease gene therapy program
* Abeona Therapeutics receives FDA orphan drug designation for ABO-201 juvenile Batten disease gene therapy program
Jan 10 Intrexon Corp
* Ziopharm and Intrexon announce cooperative research and development agreement with the National Cancer Institute utilizing sleeping beauty system to generate T Cells targeting Neoantigens Source text for Eikon: Further company coverage:
NAIROBI, June 29 Kenya has delayed plans to start crude oil production and exports until the government passes an amended law that includes setting out how revenues will be shared between national and county government and local communities.